[go: up one dir, main page]

CL2019002640A1 - Moléculas propioticas para reducir virulencia de patógenos. - Google Patents

Moléculas propioticas para reducir virulencia de patógenos.

Info

Publication number
CL2019002640A1
CL2019002640A1 CL2019002640A CL2019002640A CL2019002640A1 CL 2019002640 A1 CL2019002640 A1 CL 2019002640A1 CL 2019002640 A CL2019002640 A CL 2019002640A CL 2019002640 A CL2019002640 A CL 2019002640A CL 2019002640 A1 CL2019002640 A1 CL 2019002640A1
Authority
CL
Chile
Prior art keywords
pathogens
reduce virulence
virulence
proprietary
molecules
Prior art date
Application number
CL2019002640A
Other languages
English (en)
Inventor
Monica Angela Cella
Sarah M Curtis
Jonathon Patrick Roepke
Original Assignee
Microsintesis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microsintesis Inc filed Critical Microsintesis Inc
Publication of CL2019002640A1 publication Critical patent/CL2019002640A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/195—Proteins from microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)

Abstract

SE PROPORCIONAN PÉPTIDOS DERIVADOS DE BACTERIAS PROBIÓTICAS QUE SE UTILIZAN PARA PREVENIR Y/O TRATAR INFECCIONES NO ENTÉRICAS EN UN SUJETO. LOS PÉPTIDOS DERIVADOS DE LAS BACTERIAS PROBIÓTICAS TAMBIÉN TIENEN USO PARA REDUCIR LA VIRULENCIA DE LAS INFECCIONES NO ENTÉRICAS EN UN SUJETO. TAMBIÉN SE PROPORCIONAN COMPOSICIONES DE LOS PÉPTIDOS FORMULADOS COMO O DENTRO DE PRODUCTOS ALIMENTICIOS, BEBIDAS, SUPLEMENTOS NUTRICIONALES, MEDICAMENTOS Y SIMILARES.
CL2019002640A 2017-03-16 2019-09-16 Moléculas propioticas para reducir virulencia de patógenos. CL2019002640A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762472061P 2017-03-16 2017-03-16

Publications (1)

Publication Number Publication Date
CL2019002640A1 true CL2019002640A1 (es) 2020-05-15

Family

ID=63521745

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002640A CL2019002640A1 (es) 2017-03-16 2019-09-16 Moléculas propioticas para reducir virulencia de patógenos.

Country Status (16)

Country Link
US (2) US11912788B2 (es)
EP (1) EP3595698A4 (es)
JP (2) JP2020510096A (es)
KR (2) KR20240046640A (es)
CN (1) CN110621332A (es)
AU (2) AU2018233183A1 (es)
BR (1) BR112019019256A2 (es)
CA (1) CA3056719A1 (es)
CL (1) CL2019002640A1 (es)
EA (1) EA201992176A1 (es)
MA (1) MA51873A (es)
MX (1) MX2019011058A (es)
PE (1) PE20191783A1 (es)
PH (1) PH12019502340A1 (es)
SG (1) SG11201909606RA (es)
WO (1) WO2018165765A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ758166A (en) * 2017-03-16 2024-12-20 Microsintesis Inc Compositions and methods involving probiotic molecules
AU2018233183A1 (en) 2017-03-16 2019-10-31 Microsintesis Inc. Probiotic molecules for reducing pathogen virulence
CA3145739A1 (en) * 2019-07-02 2021-01-07 Microsintesis Inc. Quorum-sensing inhibitors and/or postbiotic metabolites and related methods
CN115039885B (zh) * 2021-05-14 2023-11-03 江苏艾兰得营养品有限公司 一种具有抑制奇异变形杆菌生长作用的副干酪乳杆菌及其益生菌组合物、发酵液和应用
GB2613406A (en) * 2021-05-14 2023-06-07 Ivc Nutrition Corp Probiotic having effect of inhibiting growth of proteus mirabilis, and fermentation broth and use thereof
KR102337951B1 (ko) * 2021-06-25 2021-12-13 주식회사 비피도 요로감염 개선, 예방 또는 치료를 위한 락토바실러스 헬베티쿠스 gut10 균주 및 이를 포함하는 조성물
KR102356423B1 (ko) * 2021-07-02 2022-02-09 (주)에스디생명공학 항균, 피부 보습, 항아토피, 피부 장벽 강화, 및 주름 개선 활성을 갖는 복합 균주를 유효성분으로 포함하는 조성물
KR102618322B1 (ko) * 2021-10-08 2023-12-27 순천향대학교 산학협력단 신규한 락토 바실러스 균주, 및 이를 포함하는 결핵 예방, 치료, 또는 개선용 조성물
CN114106096A (zh) * 2021-11-16 2022-03-01 华南理工大学 一种具有改善睡眠活性的六肽及其应用
CN114591879B (zh) * 2022-05-11 2022-12-06 中国农业大学 一种抑制幽门螺杆菌的发酵乳杆菌及其应用
KR102551065B1 (ko) * 2022-05-12 2023-07-03 중앙대학교 산학협력단 김치로부터 유래된 LAB(lactic acid bacteria)을 유효성분으로 포함하는 항-바이오필름 조성물
CN116478882A (zh) * 2023-05-05 2023-07-25 石河子大学 能够提高绵羊日增重和饲料转化率的产酸的混合菌制剂的制备方法
CN119242516A (zh) * 2024-10-31 2025-01-03 广西民族大学 一株粪稳杆菌gxun3754及其在防治象耳豆根结线虫上的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0395309B1 (en) 1989-04-28 1995-12-27 Takara Shuzo Co. Ltd. Human calpastatin-like polypeptide
FR2686085B1 (fr) 1992-01-10 1995-08-04 Agronomique Inst Nat Rech Peptides representant des fragments du cmp, anticorps diriges contre lesdits peptides, et leurs utilisations.
WO1994018832A1 (en) 1993-02-26 1994-09-01 Dana-Farber Cancer Institute, Inc. Cd4 mediated modulation of lipid kinases
US7393663B2 (en) 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
JP4476934B2 (ja) 2003-04-14 2010-06-09 明治乳業株式会社 新規ペプチドおよび免疫賦活剤、機能性食品ならびに機能性食品の製造方法
DE10317870A1 (de) * 2003-04-17 2004-11-04 Crompton Vinyl Additives Gmbh Neues Stabilisatorsystem zur Stabilisierung von halogenhaltigen Polymeren
EP1706126A4 (en) * 2003-12-04 2009-07-01 Biofilms Strategies Inc METHOD AND COMPOSITIONS FOR PREVENTING THE PREPARATION OF BIOFILMS, REDUCING EXISTING BIOFILMS, AND REDUCING EXISTING BIOFILMS AND REDUCING BACTERIA POPULATIONS
US7306677B2 (en) * 2004-01-30 2007-12-11 Boston Scientific Corporation Clamping fixture for coating stents, system using the fixture, and method of using the fixture
US8273710B2 (en) 2004-12-23 2012-09-25 Campina Nederland Holding B.V. Protein hydrolysate enriched in peptides inhibiting DPP-IV and their use
JP2009516738A (ja) * 2005-11-21 2009-04-23 ティーガスク−ザ アグリカルチャー アンド フード デベロップメント オーソリティー カゼイン由来の抗菌ペプチドおよびそれを生成するＬａｃｔｏｂａｃｉｌｌｕｓ株
US8431528B2 (en) 2008-05-16 2013-04-30 University Of Maryland, Baltimore Antibacterial Lactobacillus GG peptides and methods of use
EP2307444B1 (en) * 2008-06-27 2021-12-08 University Of Guelph Analysis of lactobacillus acidophilus la-5 signal interference molecules
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
PT105073A (pt) 2010-04-26 2011-10-26 Consejo Superior Investigacion Processo de obtenção de extractos peptídicos bioactivos através da hidrólise de proteínas de soro de leite com enzimas de cynara cardunculus, referidos extractos e respectivas utilizações
WO2014020209A1 (es) 2012-07-30 2014-02-06 Consejo Superior De Investigaciones Científicas (Csic) Uso de hidrolizados de proteínas lácteas como protectores a nivel gastrointestinal
CN104583229B (zh) * 2012-08-29 2020-06-16 新加坡科技研究局 肽及其应用
US9637523B2 (en) 2012-08-31 2017-05-02 Westfaelische Wilhelms-Universitaet Muenster Methods and peptides for preventing and treating a BCR-ABL and a C-ABL associated disease
WO2015021530A1 (en) 2013-08-12 2015-02-19 Mansel Griffiths Antiviral methods and compositions comprising probiotic bacterial molecules
AU2014343371B2 (en) * 2013-10-31 2019-03-14 Hutchison Biofilm Medical Solutions Limited Use of peptides in antibiotic resistance
JP7236216B2 (ja) 2015-04-23 2023-03-09 ナントミクス，エルエルシー がんのネオエピトープ
AU2018233183A1 (en) 2017-03-16 2019-10-31 Microsintesis Inc. Probiotic molecules for reducing pathogen virulence
NZ758166A (en) 2017-03-16 2024-12-20 Microsintesis Inc Compositions and methods involving probiotic molecules

Also Published As

Publication number Publication date
US20240150399A1 (en) 2024-05-09
KR20240046640A (ko) 2024-04-09
CN110621332A (zh) 2019-12-27
AU2018233183A1 (en) 2019-10-31
JP2020510096A (ja) 2020-04-02
EP3595698A1 (en) 2020-01-22
US11912788B2 (en) 2024-02-27
EA201992176A1 (ru) 2020-03-04
MA51873A (fr) 2020-01-22
PH12019502340A1 (en) 2020-10-19
BR112019019256A2 (pt) 2020-04-14
MX2019011058A (es) 2019-12-09
WO2018165765A1 (en) 2018-09-20
JP2023036938A (ja) 2023-03-14
AU2022203650A1 (en) 2022-06-16
CA3056719A1 (en) 2018-09-20
SG11201909606RA (en) 2019-11-28
KR20190140443A (ko) 2019-12-19
WO2018165765A9 (en) 2018-11-22
US20200017547A1 (en) 2020-01-16
AU2022203650B2 (en) 2024-04-11
EP3595698A4 (en) 2020-12-23
PE20191783A1 (es) 2019-12-24

Similar Documents

Publication Publication Date Title
CL2019002640A1 (es) Moléculas propioticas para reducir virulencia de patógenos.
AR110684A1 (es) Composiciones que comprenden cepas bacterianas y método de tratamiento
MX2022012374A (es) Composiciones multi-suplementos.
AR103260A1 (es) Modulación inmunitaria
BR112018003745A2 (pt) composições que compreendem um composto de urolitina
MX372956B (es) Novedosas cepas de lactobacillus y los usos de las mismas.
CL2016002955A1 (es) Composicion de edulcorante que comprende alulosa y un extracto de stevia; producto alimenticio o bebida que comprende la composicion edulcorante; edulcorante de mesa; uso de la composición edulcorante.
AR106644A1 (es) Composiciones nutricionales sinergísticas y usos de las mismas
MX386374B (es) Composiciones farmacéuticas y alimenticias para inducir la saciedad y prolongar la saciedad en sujetos que lo necesiten.
BR112018003780A2 (pt) composições que compreendem um composto de urolitina
MX2017007654A (es) Cepas probioticas con capacidad de absorber colesterol, métodos y usos de las mismas.
AR102085A1 (es) Composición nutricional para el entorno gastrointestinal para la provisión de un perfil metabólico y microbioma mejorados
MX2018007737A (es) Suplementos masticables de fruta.
CO2018004582A2 (es) Alimentos para aves y, en particular, alimentos para aves de corral, que comprenden derivados sintéticos de capsaicinoides y dichos alimentos para el uso prohiláctico o el tratamiento de la infección por salmonela
CO2018010937A2 (es) Sistemas de formulación para glicolípidos antimicrobianos
CL2020001975A1 (es) Composiciones y metodos de uso de cepas novedosas de lactobacillus fermentum. (divisional solicitud 201801680)
CL2017001818A1 (es) Bacteria de ácido láctico y su uso para el tratamiento de mastitis
SG10201908193PA (en) Nucleotide composition and application in food thereof
MA40645A (fr) Préparation prébiotique à base d'inuline
SG10201808326QA (en) Nutrition composition
MX2020001501A (es) Streptococcus australis como bioterapeuticos.
PH12018500164A1 (en) Gender specific synthetic nutritional compositions and nutritional systems comprising them
CL2018000344A1 (es) Composición que comprende compuestos de modulación del gusto, su uso y productos alimenticios que los contienen
MX2018001924A (es) Composiciones nutritivas sinteticas adaptadas para infantes de edades especificas, y sistemas nutritivos que las comprenden.
MX2018012312A (es) Lactobacillus rhamnosus para su uso en la preparacion de productos fermentados.